Vitas Pharma, is a drug discovery company focused on identifying and developing therapies for multidrug resistant hospital acquired infections.
The World Health Organization has identified antimicrobial resistance as 1 of 3 greatest threats to human health. Dr. Jim O'Neill, in his report on antimicrobial resistance to the British Prime Minister, says, "Drug-resistant infections could kill an extra 10 million people across the world every year by 2050 if they are not tackled. By this date they could also cost the world around $100 trillion in lost output: more than the size of the current world economy, and roughly equivalent to the world losing the output of the UK economy every year, for 35 years". It is evident that new drugs that overcome resistance and offer significant clinical benefit are urgently needed. This is the focus of the work at Vitas.
Vitas Pharma uses a proprietary screening platform to select novel compounds targeting drug resistant bacteria whilst ensuring a low propensity for resistance development.
Vitas Pharma is funded by investors from the Indian Angel Network and through Grants from the Biotechnology Industry Research Assistance Council (BIRAC), India.